AAPG revenueFY2025CN¥574.12M
- FY YoY
- -41.5%
AAPG revenue was CN¥574.12M for fiscal 2025 (ended Dec 31, 2025), down 41.5% from fiscal 2024. It rose in 2 of the last 3 fiscal years.
Ascentage Pharma Group International (AAPG) financials
For fiscal 2025 (ended Dec 31, 2025), Ascentage Pharma Group International reported CN¥574.12M of revenue and -CN¥1.24B of net income. Figures are in CNY, the currency of its SEC filings.
- Revenue, FY2025
- CN¥574.12M
- Revenue growth, YoY
- -41.5%
- Net income, FY2025
- -CN¥1.24B
- Net margin
- -216.5%
- Free cash flow, FY2025
- -CN¥1.20B
- EPS, diluted, FY2025
- -CN¥3.49
FY2022FY2025
FY2022FY2025
FY2022FY2025
AAPG revenue and earnings growth
AAPG net incomeFY2025-CN¥1.24B
AAPG net income was -CN¥1.24B for fiscal 2025 (ended Dec 31, 2025), compared with -CN¥405.43M in fiscal 2024.
AAPG EPSFY2025-CN¥3.49
AAPG diluted EPS was -CN¥3.49 for fiscal 2025 (ended Dec 31, 2025), compared with -CN¥1.34 in fiscal 2024.
AAPG free cash flowFY2025-CN¥1.20B
AAPG free cash flow was -CN¥1.20B for fiscal 2025 (ended Dec 31, 2025), compared with -CN¥135.65M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | CN¥574.12M | CN¥980.65M | CN¥221.98M | CN¥209.71M |
| Cost of revenue | CN¥48.94M | CN¥29.09M | CN¥30.54M | CN¥22.00M |
| Gross profit | CN¥525.18M | CN¥951.57M | CN¥191.44M | CN¥187.71M |
| Research and development | CN¥1.14B | CN¥947.25M | CN¥706.97M | CN¥743.10M |
| Selling, general and admin | CN¥246.28M | CN¥187.13M | CN¥181.08M | CN¥170.59M |
| Interest expense | CN¥54.07M | CN¥64.45M | CN¥96.06M | CN¥52.78M |
| Pre-tax income | -CN¥1.24B | -CN¥395.25M | -CN¥932.86M | -CN¥887.17M |
| Income tax | CN¥6.94M | CN¥10.43M | -CN¥7.15M | -CN¥4.25M |
| Net income | -CN¥1.24B | -CN¥405.43M | -CN¥925.64M | -CN¥882.92M |
| EPS, basic | -CN¥3.49 | -CN¥1.34 | -CN¥3.28 | -CN¥3.35 |
| EPS, diluted | -CN¥3.49 | -CN¥1.34 | -CN¥3.28 | -CN¥3.35 |
| Diluted shares | 356.1M | 302.1M | 282.3M | 263.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | CN¥1.20B | CN¥893.10M | CN¥1.04B | CN¥1.35B |
| Short-term investments | CN¥3.61M | CN¥9.85M | CN¥10.35M | - |
| Receivables | CN¥252.94M | CN¥83.14M | CN¥145.89M | - |
| Inventory | CN¥28.62M | CN¥6.60M | CN¥16.17M | - |
| Current assets | CN¥2.94B | CN¥1.47B | CN¥1.34B | - |
| Goodwill | CN¥24.69M | CN¥24.69M | CN¥24.69M | - |
| Current liabilities | CN¥1.64B | CN¥1.17B | CN¥934.17M | - |
| Long-term debt | CN¥757.24M | CN¥889.43M | CN¥1.18B | - |
| Total debt | CN¥757.24M | CN¥889.43M | CN¥1.18B | - |
| Total liabilities | CN¥2.63B | CN¥2.34B | CN¥2.43B | - |
| Shareholders' equity | CN¥1.32B | CN¥264.19M | CN¥70.63M | CN¥408.66M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -CN¥1.17B | -CN¥111.36M | -CN¥726.08M | -CN¥653.91M |
| Capital expenditures | CN¥27.57M | CN¥24.29M | CN¥46.11M | CN¥203.29M |
| Free cash flow | -CN¥1.20B | -CN¥135.65M | -CN¥772.18M | -CN¥857.20M |
| Investing cash flow | -CN¥1.00B | -CN¥362.04M | CN¥21.92M | -CN¥384.61M |
| Financing cash flow | CN¥2.54B | CN¥314.77M | CN¥368.75M | CN¥619.27M |
| Share repurchases | CN¥9.04M | - | CN¥5.92M | CN¥26.78M |
| Stock-based compensation | CN¥20.87M | CN¥20.92M | CN¥31.50M | CN¥22.11M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | -41.5% | 341.8% | 5.9% | - |
| Gross margin | 91.5% | 97.0% | 86.2% | 89.5% |
| Net margin | -216.5% | -41.3% | -417.0% | -421.0% |
| Free cash flow margin | -209.3% | -13.8% | -347.9% | -408.8% |
| Return on equity | -93.8% | -153.5% | -1310.5% | -216.1% |
| Current ratio | 1.79 | 1.26 | 1.44 | - |
| Debt to equity | 0.57 | 3.37 | 16.69 | - |
Source: XBRL data Ascentage Pharma Group International files with the SEC, latest filing dated Apr 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
AAPG peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AAPG | CN¥574.12M | -41.5% | -CN¥1.24B | -216.5% | $1.43B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
AAPG FAQ
8 questionsWhat is AAPG revenue?
Ascentage Pharma Group International (AAPG) reported CN¥574.12M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 41.5% from the year before.Is AAPG profitable?
No. Ascentage Pharma Group International reported a net loss of CN¥1.24B for fiscal 2025 (ended Dec 31, 2025).How fast is AAPG revenue growing?
Ascentage Pharma Group International's revenue changed -41.5% in fiscal 2025, to CN¥574.12M.What is AAPG gross margin?
Ascentage Pharma Group International's gross profit was CN¥525.18M on CN¥574.12M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 91.5%.What is AAPG free cash flow?
Ascentage Pharma Group International generated -CN¥1.20B of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -CN¥1.17B less capital expenditures.What is AAPG earnings per share?
Diluted earnings per share were -CN¥3.49 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did AAPG last report financial results?
The latest statements here come from Ascentage Pharma Group International's 20-F filed on Apr 29, 2026, covering the period ended Dec 31, 2025.Where does this AAPG financial data come from?
Quantisnow builds these statements from the structured XBRL data Ascentage Pharma Group International files with the SEC. It is provided for information only and is not investment advice.